RenovoRx CMO awarded 621,727 stock options

RenovoRx, Inc. granted its Chief Medical Officer, Ramtin Agah, stock options to purchase 621,727 shares of common stock.

Rhea-AI Filing Summary

RenovoRx, Inc. granted its Chief Medical Officer, Ramtin Agah, stock options to purchase 621,727 shares of common stock. The options have an exercise price of $0.98 per share and were approved by the Compensation Committee.

The grant consists of 319,073 shares underlying incentive stock options and 302,654 shares underlying non-qualified stock options. Vesting occurs over four years at 1/48 per month, beginning January 1, 2026, becoming fully vested on January 1, 2030. The options are exercisable only when there is an effective registration statement covering the underlying shares and will expire on April 3, 2036. Following this award, the reporting person holds 621,727 derivative securities.

Insider Trade Summary

Grant/Award: 621,727 shares

Grant/Award 1 txn

Insider Agah Ramtin

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	621,727	$0.00	$0.00

Holdings After Transaction: Stock Option — 621,727 contracts (Direct)

Footnotes (1)

1. F1. On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 621,727 shares of the Issuer's common stock (319,073 shares of which are underlying incentive stock options and 302,654 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.

Key Figures

Options granted: 621,727 options Incentive stock options: 319,073 options Non-qualified stock options: 302,654 options +5 more

8 metrics

Options granted 621,727 options Total stock options granted to CMO on April 3, 2026

Incentive stock options 319,073 options Portion of grant classified as incentive stock options

Non-qualified stock options 302,654 options Portion of grant classified as non-qualified stock options

Exercise price $0.98 per share Conversion or exercise price for the stock options

Vesting rate 1/48 per month Monthly vesting over four years with no cliff

Vesting start date January 1, 2026 Date vesting of options commences

Full vesting date January 1, 2030 Date on which options become fully vested

Expiration date April 3, 2036 Date the options expire if unexercised

Key Terms

incentive stock options, non-qualified stock options, vesting, exercise price, +1 more

5 terms

incentive stock options financial

"319,073 shares of which are underlying incentive stock options"

Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.

non-qualified stock options financial

"302,654 of which are underlying non-qualified stock options"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

vesting financial

"with such options vesting over four years at a rate of 1/48 per month"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"stock options to purchase up to 621,727 shares ... with such options vesting"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

registration statement regulatory

"The options will only become exercisable when there is an effective registration statement"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RenovoRx (RNXT) disclose in this Form 4 for Ramtin Agah?

RenovoRx reported a stock option grant to Chief Medical Officer Ramtin Agah for 621,727 shares. The award was approved by the Compensation Committee and provides the right to purchase common stock at a fixed exercise price with time-based vesting and a defined expiration date.

How many RenovoRx (RNXT) stock options were granted to the Chief Medical Officer?

The Chief Medical Officer was granted options to purchase 621,727 shares of RenovoRx common stock. These include 319,073 shares as incentive stock options and 302,654 shares as non-qualified stock options, all subject to monthly vesting over four years starting January 1, 2026.

What are the vesting terms of the RenovoRx (RNXT) stock options granted?

The options vest over four years at a rate of 1/48 per month with no cliff. Vesting begins effective January 1, 2026, and the options will be fully vested on January 1, 2030, subject to the continued service conditions implied by the vesting schedule.

What is the exercise price and expiry of the RenovoRx (RNXT) CMO’s stock options?

The granted stock options have an exercise price of $0.98 per share and expire on April 3, 2036. The options become exercisable only when there is an effective registration statement covering the underlying shares, adding a regulatory condition to their use.

When can the RenovoRx (RNXT) stock options actually be exercised?

The options may only be exercised when there is an effective registration statement covering the shares underlying the options. This means regulatory effectiveness must be in place before exercise, in addition to the time-based vesting requirements through January 1, 2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/07/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Agah Ramtin

(Last) (First) (Middle)

C/O RENOVORX, INC.

2570 W EL CAMINO REAL, SUITE 320

(Street)

MOUNTAIN VIEW CALIFORNIA 94040

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RenovoRx, Inc. [ RNXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.98	04/03/2026		A		621,727		(1)	(1)	Common Stock	621,727	$0	621,727	D

Explanation of Responses:

1. On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 621,727 shares of the Issuer's common stock (319,073 shares of which are underlying incentive stock options and 302,654 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.

	/s/ Ramtin Agah	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)